1 / 9

Vincent S. Beltrani, MD, FAAAAI Board Certified by American Academy of Dermatology American Academy Allergy, Asthma &amp

Vincent S. Beltrani, MD, FAAAAI Board Certified by American Academy of Dermatology American Academy Allergy, Asthma & Immunology. Associate Clinical Professor Department of Dermatology Department of Allergy Columbia University UMDNJ

liam
Download Presentation

Vincent S. Beltrani, MD, FAAAAI Board Certified by American Academy of Dermatology American Academy Allergy, Asthma &amp

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Vincent S. Beltrani, MD, FAAAAIBoard Certified byAmerican Academy of DermatologyAmerican Academy Allergy, Asthma & Immunology Associate Clinical Professor Department of Dermatology Department of Allergy Columbia University UMDNJ New York, New York Newark, New Jersey

  2. Atopic dermatitis is the dermatologic syndrome that frequently heralds theAtopic Diathesis

  3. Atopic dermatitis • The earlier the onset, the more severe the dermatitis. • 70% of patients with severe AD developed asthma compared with 30% of patients with mild AD, and approx. 8% in general population. • Therapies that modify the severity of AD in infants and young children might decrease the risk of the eventual development of asthma.

  4. AAD GuidelinesJAAD 2004;50:391-400Topical corticosteroids • Topical CS remain the standard of care. • Recognize complications – striae, atrophy, telengectasia, limit use. • Limited data re: optimal concentrations, duration and frequency of Rx, quantity of application, etc. • Effect and absorption by hydration &/or occlusion. • Tachyphylaxis (not documented) • Long-term intermittent use – helpful & safe.

  5. Risk factors of Topical Steroids • “Steroid phobia” • Atrophogenicity (essentially to potent CS) • Acne/rosacea-genicity • Allergic Contact Dermatitis (nonhalogenated >>halogenated CS • (?)Tachyphylaxis • Systemic absorption “Immunosuppression” Hypoadrenalism

  6. Onset of Itching/pruritus or signs of inflammation Severe flare-up Dry skin only Topical steroids Calcineuron Inhibitors Emollients Atopic Dermatitis Long-Term Management Disease severity Treatment

  7. AAD GuidelinesTopical Calcineuron Inhibitors • CI’s are safe and effective in reducing the severity of AD symptoms in children and adults. • CI’s have favorable safety profiles for up to one year of continued use. (Expert Opinion on Drug Safety 2(5):457, 2003)

  8. AAAAIDisease Management of AD(Annals Allergy Asthma Immunol 2004;93S2.) • Short-term, multicenter, blinded, vehicle- controlled studies with pimecrolimus cream 1% patients with AD have shown pimecrolimus to be both effective and safe. • Pimecrolimus cream 1% has been approved for short-term and intermittent long-term use in patients with mild-to-moderate AD who are 2 years and older.

  9. Recommendation of theCollege of Allergy • From our experience with the “negative effect” by the existing steroid-phobia, the addition of a possible “black box” warning to the label of Elidel, will result in less aggressive treatment for some patients with AD, who will then be denied effective intervention to control their atopic march.

More Related